Vident Investment Advisory LLC lifted its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 6.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 115,121 shares of the company’s stock after buying an additional 7,029 shares during the period. Vident Investment Advisory LLC owned approximately 0.16% of Myriad Genetics worth $3,954,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of MYGN. Prudential Financial Inc. raised its holdings in shares of Myriad Genetics by 3.9% during the third quarter. Prudential Financial Inc. now owns 131,073 shares of the company’s stock worth $4,742,000 after purchasing an additional 4,900 shares during the last quarter. Chartwell Investment Partners LLC raised its holdings in shares of Myriad Genetics by 31.4% during the fourth quarter. Chartwell Investment Partners LLC now owns 120,546 shares of the company’s stock worth $4,140,000 after purchasing an additional 28,831 shares during the last quarter. CS Mckee LP raised its holdings in shares of Myriad Genetics by 42.2% during the third quarter. CS Mckee LP now owns 42,650 shares of the company’s stock worth $1,543,000 after purchasing an additional 12,650 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Myriad Genetics by 43.8% during the third quarter. JPMorgan Chase & Co. now owns 297,072 shares of the company’s stock worth $10,754,000 after purchasing an additional 90,543 shares during the last quarter. Finally, Royce & Associates LP purchased a new position in shares of Myriad Genetics during the third quarter worth $990,000.
Several brokerages recently issued reports on MYGN. Goldman Sachs began coverage on shares of Myriad Genetics in a report on Monday, January 29th. They set a “sell” rating and a $32.00 target price for the company. Barclays raised their target price on shares of Myriad Genetics from $30.00 to $35.00 and gave the stock an “equal weight” rating in a report on Monday, January 22nd. BidaskClub raised shares of Myriad Genetics from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 20th. BTIG Research set a $41.00 target price on shares of Myriad Genetics and gave the stock a “buy” rating in a report on Tuesday, January 16th. Finally, Stephens set a $45.00 target price on shares of Myriad Genetics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company. Myriad Genetics presently has an average rating of “Hold” and a consensus target price of $31.42.
Myriad Genetics, Inc. (NASDAQ:MYGN) opened at $30.17 on Friday. Myriad Genetics, Inc. has a fifty-two week low of $17.50 and a fifty-two week high of $41.57. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.05 and a quick ratio of 1.81. The firm has a market cap of $2,036.14, a price-to-earnings ratio of 16.31, a price-to-earnings-growth ratio of 2.06 and a beta of 0.44.
Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, February 6th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.07. Myriad Genetics had a net margin of 16.67% and a return on equity of 9.59%. The company had revenue of $194.00 million during the quarter, compared to analysts’ expectations of $188.72 million. During the same quarter in the previous year, the company earned $0.26 earnings per share. The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. equities research analysts expect that Myriad Genetics, Inc. will post 1.15 EPS for the current fiscal year.
In other news, VP Gary A. King sold 3,120 shares of the business’s stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $38.12, for a total transaction of $118,934.40. Following the completion of the sale, the vice president now owns 125,088 shares of the company’s stock, valued at $4,768,354.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Richard M. Marsh sold 37,654 shares of the business’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $40.25, for a total transaction of $1,515,573.50. Following the sale, the vice president now directly owns 157,648 shares of the company’s stock, valued at approximately $6,345,332. The disclosure for this sale can be found here. Insiders sold 54,533 shares of company stock valued at $2,133,272 in the last ninety days. 6.70% of the stock is owned by corporate insiders.
WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/03/17/vident-investment-advisory-llc-boosts-stake-in-myriad-genetics-inc-mygn.html.
Myriad Genetics Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.